Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$31.43 USD
-0.10 (-0.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $31.44 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IART 31.43 -0.10(-0.32%)
Will IART be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Integra (IART) Stock Options
Integra's (IART) New Site to Produce Recalled Tissue Products
Why Is Integra (IART) Up 26% Since Last Earnings Report?
Other News for IART
The 3 Best Brain-Computer Interface Stocks to Buy Now
Notable earnings before Monday's open
Integra LifeSciences Holdings Q2 2024 Earnings Preview
Alltrna Announces Updates to Its Board of Directors
Integra LifeSciences price target raised by $7 at Truist, here's why